1. BCRX to present at Cantor Global Healthcare Conference on September 4, 2025. 2. The presentation time is set for 9:45 a.m. ET. 3. BCRX focuses on therapies for rare diseases and hereditary angioedema. 4. Commercialized ORLADEYO, a once-daily plasma kallikrein inhibitor. 5. Upcoming webcast may attract investor attention and interest.
The conference presentation may positively influence investor sentiment and awareness about BCRX's developments, similar to previous events where biotech companies received favorable market reactions post-presentation.
The event is crucial for ongoing investor engagement and showcasing pipeline products, likely affecting stock activity around the event date.
The presentation event is imminent, likely creating immediate interest and stock movement rather than long-term effects.
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
